Comprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks?

Similar documents
New methods for embryo selection: NGS and MitoGrade

Chromosomal Aneuploidy

NEXCCS. Your guide to aneuploidy screening

Targeted qpcr. Debate on PGS Technology: Targeted vs. Whole genome approach. Discolsure Stake shareholder of GENETYX S.R.L

Increase your chance of IVF Success. PGT-A Preimplantation Genetic Testing for Aneuploidy (PGS 2.0)


Supplementary Appendix

The effects of PGS/PGT-A on IVF outcomes

Blastocentesis: innovation in embryo biopsy

Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study

Validation of Next-Generation Sequencer for 24-Chromosome Aneuploidy Screening in Human Embryos

Detection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit

SNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation carrier and normal blastocysts

Mosaicism in human embryos: Etiology and pregnancy outcome Santi Munné

IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW

Congreso Nacional del Laboratorio Clínico 2016

EmbryoCellect TM. Pre-implantation Genetic Screening Kit TECHNICAL INFORMATION

Should Every Embryo be Screened or Frozen? What does the evidence say?

Nothing more controversial than PGS

Results of the Virtual Academy of Genetics (VAoGEN) questionnaire on Mosaicism in PGS

Progesterone and clinical outcomes

INSIDE IVF: HOW SCIENCE CARES FOR PATIENTS DR DEIRDRE ZANDER-FOX MONASH IVF GROUP HDA GRAND ROUND OCTOBER 31 ST 2018

UNDERSTANDING THE GENETIC HEALTH OF EMBRYOS

Explaining the Purpose of PGT-A. Nathan R. Treff PhD, HCLD(ABB) Chief Science Officer Clinical Laboratory Director

PGS & PGD. Preimplantation Genetic Screening Preimplantation Genetic Diagnosis

New perspectives on embryo biopsy, not how, but when and why PGS

Comprehensive chromosome screening and embryo biopsy: advantages and difficulties. Antonio Capalbo, PhD Italy

Diagnosis of parental balanced reciprocal translocations by trophectoderm biopsy and comprehensive chromosomal screening

MALBAC Technology and Its Application in Non-invasive Chromosome Screening (NICS)

USA: Livingston, NJ. PGD for infertility. Europe: Barcelona, Spain Oxford, UK Hamburg, Germany. Asia: Kobe, Japan. South America: Lima, Peru

Paul R. Brezina, Raymond Anchan & William G. Kearns

Development of new comprehensive

Preimplantation genetic diagnosis: polar body and embryo biopsy

MPS for translocations

Diagnostic Techniques to Improve the Assessment of Human IVF Embryos: Genomics and Proteomics

Telomeres and Genomic Instability In Preimplanation Embryos. David L. Keefe, M.D.

Rapid genomic screening of embryos using nanopore sequencing

Preimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC

Detecting mosaicism in trophectoderm biopsies: current challenges and future possibilities

@ CIC Edizioni Internazionali. Origin and mechanisms of aneuploidies in preimplantation embryos

CIC Edizioni Internazionali. Preimplantation genetic screening: definition, role in IVF, evolution and future perspectives. Summary.

PATIENT CONSENT FORM Preimplantation Genetic Screening (PGS) 24 Chromosome Aneuploidy and Translocation Screening with acgh

Incidence of Chromosomal Abnormalities from a Morphologically Normal Cohort of Embryos in Poor- Prognosis Patients

Scientific and Clinical Advances Advisory Committee Paper

Technical Update: Preimplantation Genetic Diagnosis and Screening

Myths About Success Rates Do they truly reflect quality of care

Rejuvenation of Gamete Cells; Past, Present and Future

INDICATIONS OF IVF/ICSI

24-Feb-15. Learning objectives. Family genetics: The future??? The traditional genetics. Genetics and reproduction in early 2015.

Same Day, Cost-Effective Aneuploidy Detection with Agilent Oligonucleotide array CGH and MDA Single Cell Amplification Method

Scientifically advanced. Personally accessible.

Differences in chromosome abnormalities in eggs and embryos between fertility centers Santi Munné

CHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS)

Hsing-Hua Lai 1, Tzu-Hsuan Chuang 1, Lin-Kin Wong 1, Meng-Ju Lee 1, Chia-Lin Hsieh 1, Huai-Lin Wang 1 and Shee-Uan Chen 2*

Case Report What Drives Embryo Development? Chromosomal Normality or Mitochondria?

Validation of a next-generation sequencing based protocol for 24-chromosome aneuploidy screening of blastocysts

ADVANCED PGT SERVICES

The Impact of ESHRE 2017 on Japanese Fertility Practice

Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation

A Stepwise Approach to Embryo Selection and Implantation Success

Application of OMICS technologies on Gamete and Embryo Selection

Problem Challenge Need. Solution Innovation Invention

Accurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays

Do it Once, Do it Right

New Innovations and Technologies:

Non-invasive methods of embryo selection

Preimplantation Genetic Diagnosis (PGD) single gene disorders. A patient guide

CHROMOSOMAL MICROARRAY (CGH+SNP)

The Chromosomal Basis Of Inheritance

PGS Embryo Screening

The ASRM Committee Opinion on PGT for Aneuploidy Our Conclusions and How We Drew Them. Alan Penzias, MD

Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University

Date of birth: / / Date of birth: / /

Understanding IVF Processes in Surrogacy

Chromosome Abnormalities

24sure TM Setting new standards in IVF

Preimplantation Genetic Testing

Date of birth: / / Date of birth: / /

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns

PG-Seq NGS Kit for Preimplantation Genetic Screening

For personal use only

Minimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology

Influence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser

Aneuploidies: the embryo point of view

1 PGS (PGS) IVF PGS, PGS,, PGS 2, PGS : (PGS); PGS; ; : R321.1 : A : X(2015) PGS 1995, 1 , (ART)

Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study

Comprehensive molecular cytogenetic analysis of the human blastocyst stage

Article Preimplantation diagnosis and HLA typing for haemoglobin disorders

2018 INFERTILITY TRENDS NATIONAL SURVEY

Chapter 15 Notes 15.1: Mendelian inheritance chromosome theory of inheritance wild type 15.2: Sex-linked genes

The Chromosomal Basis of Inheritance

Pre-implantation genetic diagnosis and pre-implantation genetic screening: two years experience at a single center

C H A P T E R Molecular Genetics Techniques for Preimplantation Genetic Diagnosis

Disclosure. Dagan Wells University of Oxford Oxford, United Kingdom

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

but it still needs a bit of work

Polar Body Approach to PGD. Anver KULIEV. Reproductive Genetics Institute

Diagnosis of human preimplantation embryo viability

Transcription:

Comprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks? Embryo 1 Embryo 2 combine samples for a single sequencing chip Barcode 1 CTAAGGTAAC Barcode 2 TAAGGAGAAC Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and Fellowship Director, Reproductive Endocrinology Sidney Kimmel Medical College, Thomas Jefferson University Scott et al Fertility and Sterility 2013; 100:697 703

100 90 80 70 % 60 50 40 With greater experience, actual negative predictive value is ~98.8% 30 20 10 0 < 32 33 35 36 38 39 40 41 42 Age (yrs) Scott et al Fertil Steril 2012; 97:870 5 Clinical Experience Misdiagnoses 4974 embryos Clinical Error Rate Per embryo 0.2% Per transfer 0.3% Per ongoing pregnancy 0.1% 3168 transfers 2976 gestations (62.1%) 10 errors 1 tetraploid 2 monosomies 7 trisomies 2354 ongoing / delivered (72.1%) Mean age 38.4 years 10 errors 7 found in losses 3 found in ongoing preg. Mosaicism evaluated in 4 samples 100% mosaic

How NextGen Sequencing Works Amplification of limited starting material Millions of small fragments are generated Embryo Biopsy NextGen Sequencing Alignment Aligned relative to a reference genome

Next Generation Sequencing Depth of Coverage Assemble all the fragments The number of fragments which fit into a given area of the genome defines the DEPTH High number of fragments allows each base pair to be sequenced/ evaluated thousands of times in a single assay depth Next Generation Sequencing Copy Number Analyses Monosomy Trisomy

Next Generation Sequencing Reality There are over three billion base pairs in the human genome There are many fewer reads per chip. Then add multiple embryos per chip. What percentage of the genome is covered with typical coverage following Whole Genome Amplification (WGA) and Next Generation Sequencing?.. <5% and typically much <1% Next Generation Sequencing Dealing with the inevitable lack of coverage WGA Divide each chromosome into a number of bins Assign each segment to a bin Count the number of mapped pieces which fall into each segment Compare and assign a copy number to that bin Integrate to assign a copy number for the chromosome ~150,000 integrated data points Numerically similar to small SNP arrays What size box is optimal? 50k 20k 10k

NextGen and SNP Array A comparison of cell lines with known abnormalities Yin et al Biol Reprod 2013; 88:(69), 1 6 Next Generation Sequencing Dealing with the inevitable lack of coverage Targeted Amplification Uses Taq based chemistry which amplifies uniformly Sequencing continues beyond the starting sequence and the remainder is locus specific which allows mapping Map each target to the appropriate locations on each chromosome Compare and assign a copy number to each location Integrate to assign a copy number for the chromosome

The Economics of NextGen and A Major Factor for Accuracy NextGen Sequencing Chip $$$$$$$ NextGen Molecular Barcoding Reduced Costs Embryo 1 Embryo 2 combine samples for a single sequencing chip Barcode 1 Barcode 2 CTAAGGTAAC TAAGGAGAAC

The Economics of NextGen A Major Factor for Accuracy NextGen Sequencing Chip $$$$$$$/2 The Economics of NextGen A Major Factor for Accuracy NextGen Sequencing Chip $$$$$$$/4

The Economics of NextGen A Major Factor for Accuracy NextGen Sequencing Chip $$$$$$$/48 The Economics of NextGen A Major Factor for Accuracy NextGen Sequencing Chip 96 or more $$$$$$$/96

Whole Genome Sequencing based NextGen (16 per chip) known trisomy copy number known monosomy unpublished data chromosome Whole Genome Sequencing based NextGen (48 per chip) copy number unpublished data chromosome

Targeted Amplification based NextGen (96 per chip) copy number unpublished data chromosome Chromosome specific cutoffs 4 NGS based copy number on chr16 3 2 chr16 specific cutoffs 1 0 unpublished data

NextGen CCS A non selection study Sustained Implantation Rate (%) 70 60 50 40 30 20 10 0 97/146 Euploid Aneuploid P<0.001 0/41 187 embryo transferred Trophectoderm biopsy Transfer prior to any analysis of the biopsy Follow up to determine the predictive value of the aneuploidy result Nextgen based CCS Targeted amplification Ion Torrent sequencing Werner et al ASRM 2015 High concordance High result rate Used the same post amplification product

Micro Duplication Grifo et al ASRM 2015 Different Diagnoses with acgh and NextGen Grifo et al ASRM 2015

Overall Euploidy Rates acgh versus NextGen Grifo et al ASRM 2015 Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts November 19, 2015 Greco E, Minasi MG, Fiorentino F Correspondence to the editor Journal Club April 19, 2016

Array CGH Based Detection of Embryonic Mosaicism Array CGH Based Detection of Embryonic Mosaicism

Outcomes of Euploid and Mosaic Embryos NGS N Miscarry Ongoing Mosaic 43 5 (12%) 11 (26%) Euploid 51 5 (10%) 26 (51%) P<0.001 Fragouli et al ASRM 2015 Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts 18 embryo transfers 6 deliveries 2 early losses 10 not pregnant Greco E et al. N Engl J Med 2015;373:2089 2090.

Single Cell Reconstitution Data +3 SD Trisomy Disomy Disomy Ovelap with Mosaic Range is ~ the range of the 2 3 SD s from mean Greco et al NEJM 2015 Single Cell Reconstitution Data +3 SD Trisomy Disomy Greco et al NEJM 2015

Back to Basics The impact of prevalence on Predictive Values Approximately 2.1% of euploid embryos will have results between 2 and 3 SD above the mean Normal Distribution The impact of random variation relative to standard deviations of the distribution Dramatic impact on the Predictive Values of a test when the prevalence of an abnormality if relatively low. Understanding a Mosaic Range Result in CCS Greco normal curve demonstrates that approximately 35% of mosaics will fall in the disomic range Results which are above trisomic threshold are typically designated trisomy even though some are likely mosaic Start with 1000 euploid embryos.. High Mosaic Range and above Disomic Mosaic 1 17 Mosaic Range 19 13 Disomic Range 930 0 Total 950 50 Mosaic Range Expectations Disomic 19/32 59% Mosaic 13/32 41% Expectation: ~60% of normal implantation rates

What does a Mosaic Range Result Mean? True State of Nature Mosaic Disomic Predictive Value of Mosaic Result for Mosaicism: 27 / (27+43) = 38.5% Lab Result Mosaic Result Non Mosaic Range 27 43 27 893 54 893 What are the anticipated delivery rates following eset? Assume no mosaic implantations 60% of the 43 = 26 Overall implantation rate of 26/ 70 = 37% Duplications and Deletions why worry? Arrays versus metaphase spread at time of amniocentesis Wopner et al NEJM December 2012 Population mostly advanced maternal age Duplications and Deletions Evaluated 80 dup/del s with known clinical phenotype 1 in 72 fetus s had a clinically significant dup/del! Risk considerably higher than for ongoing aneuploid gestation Possible to simultaneously screen for these dup/del s and aneuploidy with multiple platforms Extensive validation required

Detection of Known Duplications or Deletions in Established Cell Lines with Veriseq % Detection 100 90 80 70 60 50 40 30 20 10 0 1.4 2.5 5 6 16.3 25.5 Deletion or Duplication Size (MB) Treff et al ASRM 2015 Re evaluation of embryos with evidence of a dup/del on initial TE biopsy 28% 12% 32% 28% 32 embryos re biopsied four times to determine if the original dup/del could be confirmed Confirmed in all biopsies meiotic Confirmed in some but not all biopsies mitotic Reciprocal error in some biopsies mitotic Not found in other biopsies Scott KL et al in review 88% of initial dx confirmed Other 12% low level mosaics vs analytical errors

The Clinical Significance of Dup / Dels Next Gen using a Universal Primer and Ion Torrent Sequencing Sustained Implantation Rate (%) 70 60 50 40 30 20 10 0 P<0.001 39 229 Dup / Del Euploid Werner et al in review Lower limit of detection ~ 5 MB Mitochondrial Density Additional Parameter to Aid Selection? WGA amplification Mitochondrial Density Normalized against Alu s to control for number of cells TE biopsy Higher density associated with lower outcomes Delivered Failed

mtdna copy number is not predictive of reproductive potential among sibling embryos Paired design Evaluates test in setting where it will be applied eset inappropriate for these types of questions Delivered Not Delivered Not useful as an adjunct to embryo selection Does Embryo Biopsy Impact the Developmental Potential of the Oocyte Routine IVF Care through Retrieval Transfer the embryos Identify mature oocytes ICSI, culture, and select 2 best embryos for transfer Implantation, Maternal serum sampling for free fetal DNA and Fingerprinting Cell submitted for eventual aneuploidy screening and fingerprinting One embryo randomized to undergo biopsy N=113 pairs; 226 embryos

Overall implantation rates 39% reduction insignificant 27% (mean maternal age 32) reported by Gutierrez Mateo, C., et al. Fertility and sterility 92, 1544 1556 (2009) Evaluating the TE Biopsy Size Neal et al in review

Evaluating the TE Biopsy Size 100 90 N=1147 Percent 80 70 60 50 40 30 20 10 * P<0.01 Q1 Q2 Q3 Q4 0 Chemical pregnancy Implantation Ongoing pregnancy Live birth Outcome Neal et al in review Impact of CCS and Synchrony on Clinical Implantation Rates